Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21851857 | 0.89 | LPL (0.35) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20595129 | 0.86 | LPL (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12533489 | 0.84 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19785595 | 0.82 | — | — | |
| SCHEMBL20742776 | 0.81 | JAK2 (0.36) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1494643 | 0.81 | LPL (0.37) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL21436489 | 0.80 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL26711263 | 0.78 | LPL (0.36) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL771814 | 0.78 | CYP3A4 (0.47) | LPLLIPGMAPK1 | |
| SCHEMBL24773231 | 0.78 | LPL (0.42) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390387-B1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2021-11-17 | — | — | EP | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| EP-3390387-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | LPL 3470/4885LIPG 2413/4885CA1 4873/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | LPL 3470/4885LIPG 2413/4885CA1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.